Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Ki…

Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry ...
Zacks.com on MSN

Can Novo Nordisk Hold Its Edge as the GLP-1 Battle With LLY Heats Up?

NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for ...
PharmiWeb

EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke

Bagsværd, Denmark, 15 September 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the ...
Medical Dialogues

EMA Committee approves update to Novo Nordisk Rybelsus label to reflect cardiovascular benefits

Denmark: Novo Nordisk has announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use ...
PharmExec

Novo Nordisk’s Rybelsus Becomes First EU Approved Oral GLP-1 Reducing Severe Cardiovascular Events

Novo Nordisk's Rybelsus gains EU approval for cardiovascular benefits, enhancing treatment options for type 2 diabetes and ...
The Pharma Letter

EU approves update for Novo Nordisk’s oral semaglutide in cardio risk reduction

Committee for Medicinal Products for Human Use (CHMP) has approved Danish pharma major Novo Nordisk’s update to the Rybelsus ...
Pharmabiz

Novo Nordisk announces Ozempic reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study

Bagsværd, Denmark Saturday, September 20, 2025, 11:00 Hrs [IST] ...

Novo Nordisk A/S: EU approval makes Novo Nordisk's oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke

Oral semaglutide (Rybelsus®) is now the first and only oral GLP-1 RA approved for type 2 diabetes, with proven cardiovascular benefits1This approval is based on results from the SOUL clinical trial, w ...

Novo Nordisk: Job Cuts, Profit Guidance Shock - Why Investors Should Hold Firm

Discover why Novo Nordisk A/S’s 2025 restructuring and staff cuts shouldn't deter investors. Click to explore the long-term NVO growth potential and outlook.
Fierce Pharma

With SCOTUS appeal, AstraZeneca makes last-gasp challenge against Medicare price negotiation program

AstraZeneca is throwing one last Hail Mary following a string of Big Pharma defeats challenging the legality of the Inflation ...
Kauppalehti

Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study

Ozempic® is the only GLP-1 RA that has proven risk reduction of cardiovascular and kidney events in people with type 2 diabetes3-6. These results provide the first direct comparison of cardiovascular ...